Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by collection
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by collection
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Peripheral Blood Lymphocyte
Email alerts
Peripheral Blood Lymphocyte
Combined killing of cancer cells and cross presentation of tumor antigen by Vγ9Vδ2 T cells
Gitte Holmen
Olofsson
,
Manja
Idorn
,
Ramona
Schenker
,
Elfriede
Nössner
,
Reno
Debets
,
Bernhard
Moser
,
Özcan
Met
,
Per
thor Straten
Journal for ImmunoTherapy of Cancer
Dec 2015,
3
(Suppl 2)
P327;
DOI:
10.1186/2051-1426-3-S2-P327
Variable density of CD8+ and CD25+ programmed cell death-1 (PD-1) ligand (PD-L1) CD4+ T cells within the tumor microenvironment causes differential responses to the PD-1/PD-L1 blockade
Si-Pei
Wu
,
Yi-Long
Wu
Journal for ImmunoTherapy of Cancer
Dec 2015,
3
(Suppl 2)
P423;
DOI:
10.1186/2051-1426-3-S2-P423
A detailed characterization of peripheral blood lymphocytes in patients with myeloproliferative disease treated with pegylated-interferon alpha
Magdalena
Kovacsovics-Bankowski
,
Christy
Warby
,
Olga
Effimova
,
Todd W
Kelley
,
Soo
Kim
,
Sabina
Swierczek
,
Josef
Prchal
Journal for ImmunoTherapy of Cancer
Dec 2015,
3
(Suppl 2)
P258;
DOI:
10.1186/2051-1426-3-S2-P258
Isolation of T cell receptors specifically reactive with mutated tumor associated antigens
Maria
Parkhurst
,
Paul
Robbins
,
Steven
Rosenberg
Journal for ImmunoTherapy of Cancer
Dec 2014,
2
(Suppl 3)
P33;
DOI:
10.1186/2051-1426-2-S3-P33
Phase I/II clinical trial of anti-OX40, radiation and cyclophosphamide in patients with prostate cancer: immunological analysis
Magdalena
Kovacsovics-Bankowski
,
Lana
Chisholm
,
Jonna
Vercellini
,
Marka
Crittenden
,
Scot
Lary
,
Brendan
Curti
,
Andrew
Weinberg
Journal for ImmunoTherapy of Cancer
Nov 2013,
1
(Suppl 1)
P255;
DOI:
10.1186/2051-1426-1-S1-P255
A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors
Stephen
Ansell
,
Donald
Northfelt
,
Ian
Flinn
,
Howard
Burris
,
Shira
Dinner
,
Victor
Villalobos
,
Branimir
Sikic
,
Lana
Pilja
,
Michael
Yellin
,
Tibor
Keler
,
Thomas
Davis
Journal for ImmunoTherapy of Cancer
Nov 2013,
1
(Suppl 1)
P259;
DOI:
10.1186/2051-1426-1-S1-P259
Immune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study
Cristina
Maccalli
,
Hugues
Nicolay
,
Filippo
Capocefalo
,
Ester
Fonsatti
,
Carla
Chiarucci
,
Ornella
Cutaia
,
Diana
Giannarelli
,
Giorgio
Parmiani
,
Anna Maria
Di Giacomo
,
Michele
Maio
Journal for ImmunoTherapy of Cancer
Nov 2013,
1
(Suppl 1)
P107;
DOI:
10.1186/2051-1426-1-S1-P107
Special collections
COVID-19
(44)
Editor's choice
JITC
Basic Tumor Immunology
(531)
Case Reports
(191)
Clinical Trials Monitor
(17)
Clinical/Translational Cancer Immunotherapy
(930)
Commentary/Editorials
(139)
Computational I-O
(4)
COVID-19 and Cancer Immunotherapy
(10)
Emerging Immunotherapeutic Agents
(5)
Guidelines and Consensus Statements
(53)
Guidelines and Consensus Statements
(50)
Imaging and Immunotherapy
(8)
Immune Cell Therapies and Immune Cell Engineering
(208)
Immune Checkpoints - Beyond PD-1
(8)
Immune Checkpoints Beyond PD-1 Series
(8)
Immune Monitoring Technology Primers
(12)
Immunotherapy Biomarkers
(401)
Liquid Biopsies
(9)
Microbial-Based Cancer Immunotherapy
(4)
Oncolytic and Local Immunotherapy
(142)
Reviews
(238)
Open access
(4833)
Press releases